Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Inclusion Criteria: * Male or female 18 - 70 years of age * Histologic diagnosis of IgA nephropathy * Proteinuria \> 1 g/day or UPC \> 1 mg/mg or 113 mg/mmol at least twice * Receiving treatment with the maximum dose of ARB for at least 3 months * Patients who are willing to give written, informed consent Exclusion Criteria: * eGFR \< 15 ml/min/1.73 sq.m * UPC \>5000 mg/g or 570 mg/mmol, or \<500 mg/g or 57 mg/mmol * Serum K+ \> 5.2 mmol/L * Presence of bilateral renal artery stenosis * Presence of diabetes mellitus * Renal histology showing pathologies other than IgAN * Known allergy to ARB or DRI * Patients on ARB/ACEi combination within 12 weeks of randomization * Concurrent treatment with corticosteroids, Nsaid, or immunosuppressant * Patients with connective tissue disease or obstructive uropathy * Patients with malignancy or conditions severely limiting life expectancy * Female who are pregnant or intending to conceive * Female of child-bearing age unwilling to practice contraception * Patients who are unable to give informed consent * Patients simultaneously participating in another study